证券代码：002432 证券简称：九安医疗 公告编号：2026-007 天津九安医疗电子股份有限公司 关于2026年度第二期科技创新债券发行结果的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整， 没有虚假记载、误导性陈述或者重大遗漏。 天津九安医疗电子股份有限公司（以下简称"公司"）于2025年6月3日召开 第六届董事会第二十三次会议、第六届监事会第十八次会议，审议通过了《关于 拟注册和发行中期票据及超短期融资券的议案》。同意公司向中国银行间市场交 易商协会（以下简称"交易商协会"）申请注册发行总额不超过人民币35亿元（含 35亿元）的中期票据事项。具体内容详见公司于2025年6月5日在《证券时报》及 巨潮资讯网（http://www.cninfo.com.cn）披露的《关于拟注册和发行中期票据及超 短期融资券的公告》（公告编号：2025-049）。 公司已收到交易商协会出具的《接受注册通知书》（中市协注〔2025〕MTN749 号），交易商协会决定接受公司科技创新债券（中期票据）注册，注册金额为35 亿元，注册额度自该《接受注册通知书》落款之日起2年内有效，公司在注册有效 期内可分期发行。具 ...

证券代码：002432 证券简称：九安医疗 天津九安医疗电子股份有限公司 投资者关系活动记录表 | | 特定对象调研 分析师会议 | | | | | --- | --- | --- | --- | --- | | 投资者关系活 | 媒体采访 业绩说明会 | | | | | 动类别 | 新闻发布会 路演活动 | | | | | | 投资者线上交流会 现场参观 其他 | | | | | | 机构名称 | 人员 | 机构名称 | 人员 | | | 景顺长城基金 | 乔海英 | 上海合远 | 陈晓蕾 | | | 人保资产 | 田垒 | 华夏基金 | 孙明达 | | | 华夏基金 | 王泽实 | 农银人寿 | 赵晶 | | | 中信资管 | 彭康 | 新华养老 | 牛悦 | | | 中信保诚资产 | 王昊 | 中欧瑞博 | 肖永胜 | | 参与单位名称 及人员姓名 | 博道基金 | 张重九 | 惠升基金 | 邵雅璇 | | | 到金投资 | 万明亮 | 泰康资产 | 陈璟 | | | 理成资产 | 陈颖 | 浙商资管 | 严洋 | | | 光大永明 | 吴涛 | 宝盈基金 | 林艾灵 | | | 招银理 ...

重要内容提示： 1、天津九安医疗电子股份有限公司（以下简称"公司"或"上市公司"）股票 于 2026 年 3 月 18 日、2026 年 3 月 19 日连续 2 个交易日收盘价格涨幅偏离值累 计超过 20%。根据《深圳证券交易所交易规则》的相关规定，属于股票交易异常 波动的情况。公司近一年来股票价格持续低于公司最近一个会计年度经审计的每 股归属于公司普通股股东的净资产1。截至本公告日，公司股票价格已高于公司 最近一个会计年度经审计的每股归属于公司普通股股东的净资产，未来公司股价 存在大幅波动、下跌的风险。公司近期基本面未发生重大变化，公司股票价格受 市场情绪、概念炒作等因素影响出现大幅波动。 2、公司大类资产配置业务开始被市场关注，公司始终致力于实现资产保值 增值，并持续提升风险抵御能力。但投资过程中，受到国内外宏观经济运行、行 业周期、汇率和利率波动等多种因素影响，可能产生一定的市场风险及信用风险， 投资收益及公允价值变动也存在不确定性。此外，投资标的的赎回、出售及投资 收益的实现受到相应产品价格因素影响，需遵守相应交易结算规则及协议约定， 相比于货币资金可能存在一定的流动性风险。敬请广大投资者理性看待公 ...

本文字数：885，阅读时长大约1分钟 作者 | 一财阿驴 3月19日，A股三大指数集体收跌。沪指跌1.39%，深成指跌2.02%，创业板指跌1.11%，科创综指跌2.3%。 Wind显示，全市场近5000股下跌。 2026.03. 19 | 代码 名称 | 现价 涨跌 涨跌幅 | | --- | --- | | 000001 上证指数 | 4006.55 c -56.43 - -1.39% | | 399001 深证成指 | 13901.57 c -286.23 -2.02% | | 881001 万得全A | 6552.56 c -142.06 -2.12% | | 000680 科创综指 | 1689.34 c -39.78 -2.30% | | 399006 创业板指 | 3309.10 c -37.26 - -1.11% | 能源金属板块调整，威领股份跌停，永兴材料跌超8%，华友钴业、盛新锂能、融捷股份跌超6%。 沪深两市成交额2.11万亿元，较上一个交易日放量650亿元。 【资金流向】 主力资金全天净流入公用事业、计算机、通信等板块，净流出电子、基础化工、国防军工等板块。 具体到个股来看，九安医疗、 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology industry [3] Core Insights - The strategic position of the biopharmaceutical industry has been elevated, with innovative drugs, medical devices, and elderly care services expected to face structural opportunities in the medium to long term [2][36] - The 2026 government work report has classified the biopharmaceutical industry as a pillar industry alongside integrated circuits and aerospace, emphasizing its importance in the national economy [33][36] - There is a shift towards "full-chain support" for innovative drug development, with policies moving from macro-level support to practical payment systems, indicating a new era of diversified payment methods for innovative drugs [37][38] Summary by Sections Market Review - The biopharmaceutical index fell by 2.78% this week, underperforming the CSI 300 index by 1.71 percentage points, ranking 17th in industry performance [14] - Year-to-date, the biopharmaceutical index has increased by 0.1%, also underperforming the CSI 300 index by 0.56 percentage points, ranking 24th [14] Individual Stock Performance - In the A-share market, among 480 biopharmaceutical stocks, 75 stocks rose, accounting for 15.63%. The top five gainers were: - Yahui Pharmaceutical (+38.11%) - Zhejiang Medicine (+12.83%) - Zhongyuan Xiehe (+12.69%) - Duorui Pharmaceutical (+12.55%) - Jiuan Medical (+10.48%) [27][28] - In the Hong Kong market, 116 biopharmaceutical stocks saw 23 rise, making up 19.83%. The top ten gainers included: - Yaojie Ankang-B (+33.53%) - Deqi Pharmaceutical-B (+19.57%) - Baize Medical (+12.87%) [30][31] Industry News and Policies - The biopharmaceutical industry has been explicitly included in the national "emerging pillar industries" category, with policies aimed at enhancing multi-level medical insurance systems and promoting the development of innovative drugs and medical devices [33] - The government is encouraging commercial health insurance to cover more reasonable medical expenses outside the basic medical insurance directory, which is expected to boost investment in innovative drug development [38] Weekly Insights - The report suggests focusing on the long-term development of the biopharmaceutical industry, particularly on innovative drug and device companies that are pioneering in their fields, as well as the related industries in the silver economy [39]

经济观察网 根据2026年2月24日的市场数据，九安医疗股价表现强劲，盘中最高触及44.90元，收盘于 44.67元，单日涨幅达8.34%，突破了60日移动平均线（41.43元）。此次上涨主要受以下因素驱动： 2025年三季报显示，公司归母净利润同比增长16.11%至15.89亿元，主要受益于资产管理业务收益贡 献。华创证券指出，公司C端试剂盒业务在第三季度呈现环比增长，且新品研发（如CGM、四联检等） 持续推进。机构持仓方面，摩根医疗健康股票A在四季度增持九安医疗至62.42万股，占基金净值比例达 5.46%。 股价情况 股价突破布林带上轨（43.99元），MACD指标显示多头动能增强，KDJ指标中J线升至84.3，短期技术 面偏强。叠加所属医疗器械板块当日上涨0.69%，以及天津地域概念股表现活跃（涨1.55%），共同形 成催化。 以上内容基于公开资料整理，不构成投资建议。 资金面情况 当日主力资金净流入约9933.51万元，其中特大单买入占比显著，市场交投活跃，换手率达到5.03%。融 资融券方面，尽管2月13日出现融资净偿还，但当前融资余额11.11亿元占流通市值比例处于近一年较低 水平，可能为后续资 ...

Group 1 - The core point of the article is that Moonshot AI, the parent company of AI assistant Kimi, has completed a new funding round exceeding $700 million, led by existing investors including Alibaba and Tencent [1] - The latest funding round values Moonshot AI between $10 billion and $12 billion, indicating strong investor confidence in the company's growth potential [1] - Kimi has recently launched new features that allow for cloud deployment and integration with over 5000 community plugins, enhancing its functionality in various domains such as development, browser-related tasks, and office workflows [1] Group 2 - As of January 29, the Kimi K2.5 model has been released, significantly improving Kimi Agent's capabilities in Microsoft Office applications, including Word, PDF, Excel, and PowerPoint [2] - Moonshot AI was founded in March 2023 and aims to optimize the conversion of energy into intelligence through collaborative product development with users [2] - By the end of last year, Moonshot AI had completed five funding rounds, including a $500 million Series C round in December 2022, with investments from IDG Capital, Alibaba, and Tencent [2]

Group 1 - The company, Jiuan Medical, reported that as of the end of January 2026, the number of shareholders is approximately 68,600 [1] - The company expressed gratitude for the investor's inquiry regarding shareholder information [1] Group 2 - The inquiry was made through an interactive platform, indicating active engagement from investors [1] - The response from the company reflects transparency in shareholder communication [1]

Investment Rating - The report indicates a positive outlook for the company, with an expected net profit of 2.02 billion to 2.35 billion yuan for 2025, representing a year-on-year growth of 21.05% to 40.83% [2][3]. Core Insights - The company's performance in 2025 is primarily driven by strong results in its asset management business, despite a decline in its core operations [2][15]. - For the first three quarters of 2025, the company reported revenues of 1.069 billion yuan, with a net profit of 1.589 billion yuan, indicating that total operating costs exceeded revenues [4][5]. - The total assets under management reached 24.122 billion yuan by the end of Q3 2025, highlighting the significant contribution of asset management to the company's profitability [8]. Financial Performance - The expected net profit for 2025 is projected to be between 2.02 billion and 2.35 billion yuan, with a growth rate of 21.05% to 40.83% compared to the previous year [2][3]. - The company’s investment income for the first three quarters of 2025 was 562 million yuan, with fair value changes contributing 1.251 billion yuan, totaling over 1.8 billion yuan in investment-related income [5]. - The company holds trading financial assets worth 10.362 billion yuan, primarily in wealth management products, and other financial assets totaling 10.245 billion yuan, including hedge funds and private equity investments [6][8]. Core Business Performance - The iHealth product line, which includes smart medical devices, has seen a significant decline in revenue, with a 50% drop in the first half of 2025 compared to the previous year [10][11]. - The total revenue from iHealth products for the first three quarters of 2025 was reported at 601 million yuan, reflecting a 49% year-on-year decrease [11][12]. Market Position - The company's price-to-book (PB) ratio is currently at 0.89, indicating that it is trading below its book value, which may attract investors looking for undervalued assets [14]. - The company has substantial cash-like assets totaling 27.6 billion yuan, with short-term borrowings of only 2.334 billion yuan, suggesting a strong liquidity position [14].

Core Viewpoint - Jiuan Medical (002432.SZ) is expected to achieve a net profit of 2.02 billion to 2.35 billion yuan in 2025, representing a year-on-year growth of 21.05% to 40.83% primarily driven by strong performance in asset management business [1][13]. Financial Performance - For the first three quarters of 2025, Jiuan Medical reported revenue of 1.069 billion yuan, but net profit reached 1.589 billion yuan, with total operating costs exceeding revenue at 1.276 billion yuan [3][15]. - Investment income for the same period was 562 million yuan, and fair value changes contributed 1.251 billion yuan, totaling over 1.8 billion yuan in income from these sources [3][15]. - The company’s net profit attributable to shareholders is projected to grow by 21.05% to 40.83% compared to the previous year [2][14]. Asset Management - As of the end of Q3 2025, Jiuan Medical held trading financial assets worth 10.362 billion yuan, primarily in wealth management products, along with fixed-income securities and equity investments totaling 13.877 billion yuan [4][16]. - The total assets under management reached 24.122 billion yuan, indicating a significant contribution from asset management to overall profitability [5][18]. Product Performance - The iHealth product line, which includes smart medical devices, has seen a significant decline in revenue, with a 50% drop in the first half of 2025 compared to the previous year [8][21]. - Overall revenue from the iHealth series decreased by 49% in the first three quarters of 2025 [9][20]. Market Position - Jiuan Medical's price-to-book (PB) ratio is currently at 0.89, indicating it is trading below its book value [11][23]. - The company has substantial cash-like assets totaling 27.6 billion yuan, with short-term borrowings of only 2.334 billion yuan, suggesting a strong liquidity position [11][23].